toxylact: a02ab02 algedrate
The first professional lActological database in the word
Algedrate (A02AB02) is generally considered compatible with breastfeeding when used in standard doses, with only minimal transfer of aluminum into breast milk and no documented adverse effects in healthy term infants.
Overview of algedrate and lactation
Algedrate (algeldrate) is an aluminum hydroxide‑based antacid used to relieve heartburn, dyspepsia and gastroesophageal reflux. Aluminum from these antacids leads to only a small, transient rise in maternal plasma aluminum levels and does not significantly concentrate in breast milk. Human milk normally contains much lower aluminum concentrations than standard infant formulas, which further reduces relative exposure for the breastfed infant.
Transfer into breast milk
Available pharmacokinetic data show that after oral ingestion of aluminum antacids, maternal plasma aluminum increases modestly and returns to baseline within a few hours. Aluminum does not accumulate in breast milk to clinically relevant levels, and measured concentrations remain low compared with formula‑fed infants’ intake. High protein binding and low lipid solubility limit passage of aluminum compounds into milk, consistent with general principles of drug transfer into human milk.
Potential effects on the breastfed infant
Clinical reports have not demonstrated adverse effects in term breastfed infants exposed to maternal algedrate at therapeutic doses. Because oral bioavailability of aluminum from milk is low, systemic absorption in the infant is minimal, although intestinal permeability may be higher in premature or very young newborns. Expert sources therefore categorize algedrate as “compatible” with breastfeeding, while advising avoidance of chronic or excessive maternal use and recommending routine clinical observation of the infant.
Clinical recommendations for breastfeeding mothers
Short‑term, on‑demand use of algedrate at the lowest effective dose is considered acceptable in healthy breastfeeding dyads. To further minimize infant exposure, some lactation‑medicine experts suggest taking doses immediately after a feed and avoiding unnecessary prolonged therapy. Additional caution is advisable in mothers of preterm infants, neonates with renal impairment, or infants with compromised intestinal function, where closer monitoring or alternative therapies may be preferable.
Counseling and monitoring points
When counseling breastfeeding mothers, emphasize that algedrate‑containing antacids are not among the medications generally contraindicated in lactation and are listed as compatible in specialist lactation resources. Mothers should be advised to seek medical review if they require long‑term antacid therapy, or if the infant develops unexplained gastrointestinal symptoms, poor weight gain, or unusual irritability while the drug is being taken.
